No Data
Express News | Inhibikase Therapeutics Inc - Terminates Atm Agreement With With H.c. Wainwright & Co LLC Effective December 11, 2024
Inhibikase Therapeutics Files to Sell 58.31M Shares of Common Stock for Holders
Express News | Inhibikase Therapeutics Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After Reporting Worse-than-expected Q3 EPS Results Yesterday
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5
Inhibikase Therapeutics' Promising Developments and Financial Backing Justify Buy Rating
Inhibikase Therapeutics GAAP EPS of -$0.65 Misses by $0.17
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...